Skip to main content
Erschienen in: World Journal of Surgery 6/2010

01.06.2010

Risks and Adequacy of an Optimized Surgical Approach to the Primary Surgical Management of Papillary Thyroid Carcinoma Treated During 1999–2006

verfasst von: Clive S. Grant, John M. Stulak, Geoffrey B. Thompson, Melanie L. Richards, Carl C. Reading, Ian D. Hay

Erschienen in: World Journal of Surgery | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Intense disease surveillance and frequent lymph node metastases (LNMs) in papillary thyroid cancer (PTC) have resulted in increased locoregional recurrences. We examined the safety and efficacy of an optimized surgical approach including preoperative ultrasonograpy (US), bilateral thyroidectomy, routine compartment VI dissection, and lateral neck dissection for LNM.

Methods

During 1999–2006, a total of 420 patients underwent optimized primary surgery; 291(69%) females, median age 46 years; follow-up 98%, median 4.4 years. Patients were reviewed for tumor characteristics, pattern of LNM, staging, and outcomes.

Results

Total or near-total thyroidectomy was performed in 212 (51%) and 208 (49%) patients, respectively. Tumors were multicentric, 40% (average 1.7 cm); were bilateral, 30%; and showed extrathyroidal extension, 17%. Overall, 223 (53%) patients had LNMs: 213 (51%) were central and 85 (20%) were lateral jugular. pTNM staging: I, 258 (61%); II, 35 (8%); III, 88 (21%); IV, 39 (9%). AGES (age, grade, extension, and size—thyroid tumor; and MACIS (metastasis, age, completeness of resection, invasion, and size) prognostic scores were low risk in 362 (86%) and 352 (84%), respectively. Relapse developed in 57 (14%) patients: LNM in 44, soft tissue local recurrence (LR) in 5, distant metastases (DM) in 8. Hypoparathyroidism occurred in 5 (1.2%) patients and 1 had unintentional laryngeal nerve damage. Relapse with LNM occurred in previously operated fields in 19 (5%) patients, 11(3%) from disease virulence (LR or DM), preoperative false-negative (FN) US in 12 (3%), and combination of FN-US and recurrence in the operated field in 5 (1%) patients.

Conclusions

Recurrence was limited to 5% of patients when the extent of disease was accurately defined and potentially curable. This optimized surgical strategy is relatively safe.
Literatur
1.
Zurück zum Zitat Hay ID, Grant CS, Taylor WF et al (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095PubMed Hay ID, Grant CS, Taylor WF et al (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095PubMed
2.
Zurück zum Zitat Hay I, Thompson G, Grant C et al (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885CrossRefPubMed Hay I, Thompson G, Grant C et al (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885CrossRefPubMed
3.
Zurück zum Zitat Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947–953PubMed Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947–953PubMed
4.
Zurück zum Zitat American Thyroid Association Guidelines Task Force (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:1–33CrossRef American Thyroid Association Guidelines Task Force (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:1–33CrossRef
5.
Zurück zum Zitat Thyroid Carcinoma Task Force (2001) AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma—American Association of Clinical Endocrinologists, American College of Endocrinology. Endocr Pract 7:203–220 Thyroid Carcinoma Task Force (2001) AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma—American Association of Clinical Endocrinologists, American College of Endocrinology. Endocr Pract 7:203–220
6.
Zurück zum Zitat Bilimoria K, Bentrem D, Ko C et al (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:275–384 Bilimoria K, Bentrem D, Ko C et al (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:275–384
7.
Zurück zum Zitat Anonymous (2007) Thyroid carcinoma. In: NCCN clinical practice guidelines in oncology. 2.2007 ed. www.nccn.org Anonymous (2007) Thyroid carcinoma. In: NCCN clinical practice guidelines in oncology. 2.2007 ed. www.​nccn.​org
8.
Zurück zum Zitat Greene F, Page D, Fleming I et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York Greene F, Page D, Fleming I et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York
9.
Zurück zum Zitat Fleming I, Cooper J, Henson D (eds) (1997) American Joint Committee on cancer: AJCC cancer staging manual. Lippincott-Raven, Philadelphia Fleming I, Cooper J, Henson D (eds) (1997) American Joint Committee on cancer: AJCC cancer staging manual. Lippincott-Raven, Philadelphia
10.
Zurück zum Zitat Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1058PubMed Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1058PubMed
11.
Zurück zum Zitat DeGroot L, Kaplan E, McCormick M et al (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–424CrossRefPubMed DeGroot L, Kaplan E, McCormick M et al (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–424CrossRefPubMed
12.
Zurück zum Zitat Moley J, Wells S (1999) Compartment-mediated dissection for papillary thyroid cancer. Langenbecks Arch Surg 384:9–15CrossRefPubMed Moley J, Wells S (1999) Compartment-mediated dissection for papillary thyroid cancer. Langenbecks Arch Surg 384:9–15CrossRefPubMed
13.
Zurück zum Zitat Anonymous (2008) Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19:ii99–ii101 Anonymous (2008) Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19:ii99–ii101
14.
Zurück zum Zitat Zimmerman D, Hay I, Gough I et al (1988) Papillary thyroid cancer in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 104:1157–1166PubMed Zimmerman D, Hay I, Gough I et al (1988) Papillary thyroid cancer in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 104:1157–1166PubMed
15.
Zurück zum Zitat Vassilopoulou-Sellin R, Schultz P, Haynie T (1996) Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78:493–501CrossRefPubMed Vassilopoulou-Sellin R, Schultz P, Haynie T (1996) Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78:493–501CrossRefPubMed
16.
Zurück zum Zitat Mazzaferri E, Young R, Oertel J et al (1977) Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 56:171–196 Mazzaferri E, Young R, Oertel J et al (1977) Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 56:171–196
17.
Zurück zum Zitat Lundgren C, Hall P, Dickman P et al (2005) Clinically significant prognostic factors for differentiated thyroid carcinoma. Cancer 106:524–531CrossRef Lundgren C, Hall P, Dickman P et al (2005) Clinically significant prognostic factors for differentiated thyroid carcinoma. Cancer 106:524–531CrossRef
18.
Zurück zum Zitat Loh KC, Greenspan F, Gee L et al (1997) Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553–3562CrossRefPubMed Loh KC, Greenspan F, Gee L et al (1997) Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553–3562CrossRefPubMed
19.
Zurück zum Zitat Gagel R, Goepfert H, Callender D (1996) Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 46:261–283CrossRefPubMed Gagel R, Goepfert H, Callender D (1996) Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 46:261–283CrossRefPubMed
20.
Zurück zum Zitat Voutilainen P, Multanen M, Leppaniemi A et al (2001) Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 11:953–957CrossRefPubMed Voutilainen P, Multanen M, Leppaniemi A et al (2001) Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 11:953–957CrossRefPubMed
21.
Zurück zum Zitat Heemstra K, Liu Y, Stokkel M et al (2007) Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 66:58–64 Heemstra K, Liu Y, Stokkel M et al (2007) Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 66:58–64
22.
Zurück zum Zitat Mazzaferri E (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498–512PubMed Mazzaferri E (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498–512PubMed
23.
Zurück zum Zitat Kloos R, Mazzaferri E (2005) A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047–5057CrossRefPubMed Kloos R, Mazzaferri E (2005) A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047–5057CrossRefPubMed
24.
Zurück zum Zitat Sawka A, Thephamongkhol K, Brouwers M et al (2004) A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676CrossRefPubMed Sawka A, Thephamongkhol K, Brouwers M et al (2004) A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676CrossRefPubMed
25.
Zurück zum Zitat Stulak J, Grant C, Farley D et al (2006) Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 141:489–496CrossRefPubMed Stulak J, Grant C, Farley D et al (2006) Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 141:489–496CrossRefPubMed
26.
Zurück zum Zitat Sywak M, Cornford L, Roach P et al (2006) Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140:1000–1007CrossRefPubMed Sywak M, Cornford L, Roach P et al (2006) Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140:1000–1007CrossRefPubMed
27.
Zurück zum Zitat Bonnet S, Hartl D, Leboulleux S et al (2009) Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 94:1162–1167CrossRefPubMed Bonnet S, Hartl D, Leboulleux S et al (2009) Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 94:1162–1167CrossRefPubMed
28.
Zurück zum Zitat Noguchi S, Murakami N (1987) The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am 67:251–261PubMed Noguchi S, Murakami N (1987) The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am 67:251–261PubMed
29.
Zurück zum Zitat Ozaki O, Kunihiko I, Kobayashi K et al (1988) Modified neck dissection for patients with nonadvanced, differentiated carcinoma of the thyroid. World J Surg 12:825–829CrossRefPubMed Ozaki O, Kunihiko I, Kobayashi K et al (1988) Modified neck dissection for patients with nonadvanced, differentiated carcinoma of the thyroid. World J Surg 12:825–829CrossRefPubMed
30.
Zurück zum Zitat Hay I, Bergstralh E, Grant C et al (1999) Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery 126:1173CrossRefPubMed Hay I, Bergstralh E, Grant C et al (1999) Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery 126:1173CrossRefPubMed
31.
Zurück zum Zitat Roh JL, Park JY, Park C (2007) Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 245:604–610CrossRefPubMed Roh JL, Park JY, Park C (2007) Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 245:604–610CrossRefPubMed
32.
Zurück zum Zitat Porterfield J, Factor D, Grant C (2009) Operative technique for modified radical neck dissection in papillary thyroid carcinoma. Arch Surg 144:567–574CrossRefPubMed Porterfield J, Factor D, Grant C (2009) Operative technique for modified radical neck dissection in papillary thyroid carcinoma. Arch Surg 144:567–574CrossRefPubMed
Metadaten
Titel
Risks and Adequacy of an Optimized Surgical Approach to the Primary Surgical Management of Papillary Thyroid Carcinoma Treated During 1999–2006
verfasst von
Clive S. Grant
John M. Stulak
Geoffrey B. Thompson
Melanie L. Richards
Carl C. Reading
Ian D. Hay
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 6/2010
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-009-0307-9

Weitere Artikel der Ausgabe 6/2010

World Journal of Surgery 6/2010 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.